Live Earnings Conference Call: Lexeo Therapeutics' Q3 2026 & Study result earnings call is happening now. NASDAQ:LXEO Lexeo Therapeutics Q3 2026 & Study result Earnings Date & Estimates $2.87 0.00 (0.00%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$3.61 +0.74 (+25.78%) As of 08:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Lexeo Therapeutics is estimated to report Q3 2026 & Study result earnings on Monday, December 14, 2026. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026 & Study resultAnnouncement DateDecember 14, 2026 Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) Live Call not available Live EventEarnings Conference CallLexeo Therapeutics Q3 2026 & Study result00:00 / 00:00Live Transcript Follow Audio What Analysts Expect from Lexeo Therapeutics in Q3 2026 & Study resultLexeo Therapeutics is expected to post earnings of -$0.3222 per share. In the same quarter a year earlier Lexeo Therapeutics reported -$0.33 per share. Lexeo Therapeutics last reported on August 12, 2026, posting -$0.30 per share and missing the -$0.2852 consensus estimate. Lexeo Therapeutics has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.3222Prior-Year EPS-$0.33Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.30 (Missed by -$0.0148)EPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 & Study result CallSlide DeckPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Q2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Lexeo Therapeutics Q3 2026 & Study result Earnings FAQ When does Lexeo Therapeutics report Q3 2026 & Study result earnings? Lexeo Therapeutics (NASDAQ:LXEO) is estimated to report Q3 2026 & Study result earnings on Monday, December 14, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Lexeo Therapeutics' Q3 2026 & Study result earnings call? Lexeo Therapeutics' Q3 2026 & Study result earnings conference call is scheduled for Monday, November 16, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Lexeo Therapeutics? Analysts expect Lexeo Therapeutics to post earnings of -$0.3222 per share for Q3 2026 & Study result. Lexeo Therapeutics Earnings HeadlinesLexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial ...20 minutes ago | finance.yahoo.comLexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results1 hour ago | globenewswire.comTrump, Schiff and Dalio all point to the same warning signIn 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't made whole until age 85. Today, the national debt sits at 38.86 trillion dollars, a level the market has never faced before. Economists including Peter Schiff and Ray Dalio point to a classic bubble forming.November 16 at 1:00 AM | USA Capital Gold (Ad)Lexeo Therapeutics Announces Date for Third Quarter 2026 Financial Results and Business Update on HEROIC-PKP2 TrialNovember 15 at 9:51 AM | quiverquant.comQLexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026November 15 at 9:44 AM | markets.businessinsider.comLexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026November 15 at 7:00 AM | globenewswire.comSee More Lexeo Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lexeo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexeo Therapeutics and other key companies, straight to your email. Email Address About Lexeo TherapeuticsLexeo Therapeutics (NASDAQ:LXEO) is a clinical-stage biotechnology company developing gene therapies for inherited cardiovascular and other serious diseases. Its research focuses on using genetic medicines to address conditions caused by specific gene mutations. The company’s investigational programs include LX2006, a gene therapy being studied for Friedreich ataxia cardiomyopathy, and other candidates targeting genetically defined heart diseases. These therapies remain in development and are not established commercial products. Founded in 2017, Lexeo is based in New York and conducts research and clinical development in the United States. As a clinical-stage company, it focuses on advancing its pipeline rather than marketing approved therapies.View Lexeo Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?Applied Materials Beats and Raises, But Investors Stay Unconvinced3 Power and Grid Stocks That Could Keep Growing Even if AI Spending SlowsYETI Beat on Earnings, But Its Sales Tell a Different Story Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.